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Abstract: Resistance to β-lactam antibacterials, importantly via production of β-lactamases, threatens
their widespread use. Bicyclic boronates show promise as clinically useful, dual-action inhibitors
of both serine- (SBL) and metallo- (MBL) β-lactamases. In combination with cefepime, the bicyclic
boronate taniborbactam is in phase 3 clinical trials for treatment of complicated urinary tract infections.
We report kinetic and crystallographic studies on the inhibition of AmpC, the class C β-lactamase
from Escherichia coli, by bicyclic boronates, including taniborbactam, with different C-3 side chains.
The combined studies reveal that an acylamino side chain is not essential for potent AmpC inhibition
by active site binding bicyclic boronates. The tricyclic form of taniborbactam was observed bound
to the surface of crystalline AmpC, but not at the active site, where the bicyclic form was observed.
Structural comparisons reveal insights into why active site binding of a tricyclic form has been
observed with the NDM-1 MBL, but not with other studied β-lactamases. Together with reported
studies on the structural basis of inhibition of class A, B and D β-lactamases, our data support the
proposal that bicyclic boronates are broad-spectrum β-lactamase inhibitors that work by mimicking a
high energy ‘tetrahedral’ intermediate. These results suggest further SAR guided development could
improve the breadth of clinically useful β-lactamase inhibition.
Keywords: antibiotic resistance; β-lactam antibacterial; bicyclic boronate inhibitors;
VNRX-5133/taniborbactam; vaborbactam; metallo- and serine-β-lactamase inhibition; transition
state analogue
1. Introduction
The β-lactams are amongst the most important antibiotics [1], but their widespread use is
challenged by resistance, substantially through the global dissemination ofβ-lactamases [2,3]. There are
two structural/mechanistic groups of β-lactamases—the nucleophilic serine-β-lactamases (SBLs:
Ambler classes A, C, D) and the zinc dependent metallo-β-lactamases (MBLs: Ambler class B)
(Figure 1b) [4]. Treatment of bacterial infections exhibiting resistance via some SBLs, particularly
class A enzymes, was substantially advanced by the co-administration of a β-lactam antibiotic with a
β-lactam-based SBL inhibitor, i.e., clavulanic acid [5,6], sulbactam [7], or tazobactam [8] (Figure 1a).
However, these inhibitors are inactive, or are insufficiently active, against most class C SBLs, class
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A carbapenemases, and class B MBLs [3]. The clinical introduction of avibactam and avibactam
derivatives such as relebactam [9] was an important step in more broadly combating SBLs because
avibactam is active against class A β-lactamases (including carbapenemases), class C β-lactamases,
and some class D β-lactamases [10]. Avibactam is also important because it demonstrates the clinical
viability of non-β-lactam-based β-lactamase inhibition [11]. However, there is emerging SBL-mediated
resistance to avibactam [12,13] and MBLs can hydrolyze avibactam, albeit slowly [14], suggesting that
its future use may be compromised by the evolution of new β-lactamases [14,15].
Figure 1. Mechanistic basis for β-lactamase inhibition by (bi)cyclic boronates. (a) clinically used
β-lactamase inhibitors; (b) outline general mechanisms of SBLs and MBLs, exemplified by hydrolysis
of a cephalosporin with elimination at C-3’. The tetrahedral intermediates, common to both SBL
and MBL catalysis, may be mimicked by the sp3 form of (bi)cyclic boronates; (c) equilibria between
sp2- and sp3-hybridized forms of mono- and bi-cyclic boronates; (d) structures of bicyclic boronate
β-lactamase inhibitors cyclic boronate 1 (CB1), cyclic boronate 2 (CB2), the thioether boronate (CB3),
and taniborbactam (TAN, formerly VNRX-5133). Note that the CB3 used in this study contained a
mixture of the (3S)- and (3R)-enantiomers (~1:3, respectively) [16].
By contrast with the successes in inhibiting SBLs, to date, there are no clinically useful MBL
inhibitors [3]. There is thus interest in development of non-acylating β-lactamase inhibitors, especially
those exhibiting dual-action SBL and MBL inhibition. Boron-based compounds have long been known
as SBL and, more recently, MBL inhibitors [17]. After early work on acyclic boronic acids, recent efforts
have focused on cyclic boronates. One such compound, the (predominantly) monocyclic boronic
acid vaborbactam [18] (VAB, Figure 1c) which is approved for treatment of complicated urinary
tract infections (cUTI) in co-administration with meropenem [19]. Vaborbactam is a relatively potent
inhibitor of class A ESBLs and the KPC carbapenemases, but is not, at least usefully, active against tested
MBLs and clinically relevant class C and D SBLs [19]. By contrast, boronates that are predominantly
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bicyclic in solution, are able to inhibit many, but not all, of the tested representatives of all four Ambler
β-lactamase classes [20,21]. The bicyclic boronates are proposed to work by binding in a manner
analogous to that of the tetrahedral intermediate(s) likely involved in β-lactam catalyzed hydrolysis
by both SBLs and MBLs [20,21] (Figure 1b). Taniborbactam (TAN, formerly VNRX-5133, Figure 1d)
has passed phase 1 clinical testing [22] and is currently in phase 3 clinical testing in combination with
cefepime (registration No. NCT03840148 at ClinicalTrials.gov). TAN has been shown to successfully
inhibit SBLs and MBLs in vitro [23–26], and to restore cefepime’s activity in vivo against a class A SBL
(CTX-M-14) producing strain of Klebsiella pneumoniae in a neutropenic lung model of infection as well
as CTX-M-15 expressing E. coli in ascending urinary tract infections in mice [26].
Many β-lactamases are encoded by plasmids, but the AmpC type β-lactamases that are present
in most Escherichia coli strains are chromosomally encoded [27]. While normally expressed at low
levels, mutations in the ampC gene promoter and/or attenuator regions can lead to constitutive
hyperproduction of AmpC in E. coli [28,29]. This is clinically relevant because E. coli is a common
Gram-negative pathogen, which is often responsible for bloodstream infections [30].
Structural data on the modes of action of bicyclic boronate β-lactamase inhibitors are relatively
limited [20,21,24,26,31–33]. Work to date indicates that more than one side chain binding mode can
occur, making structure-guided optimization challenging. Work on the B1 subfamily MBL NDM-1 has
shown partial cyclisation of the TAN acylamino side chain to form a tricyclic structure, as an observed
bound at the NDM-1 active site by protein crystallography [24]. The extent to which such tricyclisation
contributes to β-lactamase inhibition more generally is unclear.
To enable future efforts on the optimization of bicyclic boronates, we report crystallographic and
kinetic studies on inhibition of the clinically important class C AmpC β-lactamase from Escherichia coli
(AmpCEC) by TAN, a previously reported model bicyclic boronate 2 (CB2) [20,21,34], and a thioether
bicyclic boronate derivative (CB3) that we have recently shown to have enhanced potency against
some SBLs and MBLs in vitro [16,35]. Together with previously reported studies [20,21,24,26,31–33],
the crystallographic results support the proposal that bicyclic boronates mimic the tetrahedral
intermediate(s) common to both SBL and MBL catalysis. The results indicate scope for the modification
of the C-3 side chain of bicyclic boronates to improve potency towards AmpC type β-lactamases and
inform on the likelihood of tricycle formation.
2. Materials and Methods
2.1. Materials
CB2, TAN, and CB3 were prepared as previously described [16,20,24]; VAB was purchased from
Cayman Chemical (An Arbor, MI, USA). FC-5 was prepared as previously described [36].
2.2. Enzyme Production
Recombinant AmpC from Escherichia coli was produced according to a modification of the reported
protocol [37]. In brief, AmpCEC was produced using the pAD7 vector [38] in E. coli W3110 cells
using 2TY media supplemented with 12.5 mg/mL tetracycline. Cells were grown overnight at 37 ◦C,
harvested via centrifugation (10 min, 12,000× g, 4 ◦C), resuspended in 50 mL lysis buffer (20 mM Tris pH
7.5, 10 mM MgCl2, 50 µg/mL DNAse I), then lyzed via sonification. Subsequent chromatography steps
employed ÄKTA (GE Healthcare, Chicago, IL, USA) FPLC machines. The resultant supernatant was
dialyzed with three buffer exchanges of 300 mL 10 mM Tris pH 6.75, then loaded onto a SP Sepharose
(GE Healthcare, Chicago, IL, USA) cation exchange column and gradually eluted using a gradient
of 10–75 mM Tris pH 7.0. Fractions containing the purified protein were pooled and concentrated to
20 mg/mL using an Amicon Ultra (MilliporeSigma, Burlington, MA, USA) centrifugal filter (15 mL,
10kDa MWCO). The protein was highly purified (>95%) as judged by SDS-PAGE and electrospray
ionization mass spectrometry analyses (observed mass: 39,551 Da, calculated mass: 39,551 Da).
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2.3. Kinetics
All kinetic measurements were carried out in competition assays using the fluorescent substrate
FC-5 [36] under steady-state conditions monitoring hydrolysis, in 100 mM phosphate buffer pH 7.5
supplemented with 0.01% (v/v) Triton X-100 (Assay Buffer). Fluorescence was measured using a
PHERAstarFS (BMG Labtech, Aylesbury, United Kingdom) plate-reader, recording emission spectra
at λex = 380 nm and λem = 460 nm. IC50s were determined after 10 min incubation time of 500 pM
AmpCEC with varying concentrations of inhibitors and assayed using 5 µM FC-5. Nonlinear regression
analyses were carried out using GraphPad Prism V. 5.04 (GraphPad Software, San Diego, CA, USA).
As described for avibactam inhibition [11], the kinetics of bicyclic boronate inhibition of
β-lactamases can be described assuming a two-step, reversible inhibition model:
E+ I
k1−−−→←−−−
k−1
E : I
k2−−−→←−−−
k−2
E− I (1)
with E: enzyme; I: inhibitor; k1: association rate constant; k−1: dissociation rate constant; k2: binding
rate constant, and k−2: recyclization rate constant.
To obtain the pseudo first-order rate constant kobs and the apparent inhibition constant Kiapp,
the rate of FC-5 (5 µM) hydrolysis by AmpCEC (100 nM) was measured in the presence of varying
concentrations of the inhibitor. Time-courses were then first fitted to Equation (2) to give the observed
initial rate constants kobs as previously described [39]:
P = Vst+ (V0 −VS)
(
1− e−kobst
)
kobs
+ P0 (2)
with P: formed product, proportional to fluorescence signal; P0: initial fluorescence; VS: velocity of
no-inhibitor control; and V0: velocity of no-enzyme control to estimate a fully inhibited enzyme.
Plotting the resultant kobs values against the inhibitor concentration [I] (Figure S1b) and fitting to
Equation (3) gives the apparent second-order rate constant (k2/K’)
kobs = k2 +
k2
K′ ∗ [I] (3)
with K’ representing the equilibrium coefficient of AmpCEC inhibition in the presence of FC-5 in the set
concentration of 5 µM.
This can then be corrected using the Michaelis constant (KM) of FC-5 for AmpCEC and the FC-5
concentration [S] according to Equation (4) to give the second-order rate constant (k2/K):
k2
K
=
k2
K′ ∗
(
[S]
KM
+ 1
)
(4)
The same data were used to determine the apparent inhibition constant Kiapp [40]. The reciprocals
of the initial rates were plotted against inhibitor concentration (Figure S1a), giving a straight line for
which the value of the intercept divided by the slope gives Kiapp’. From this, Kiapp can be obtained
after correction with the KM for FC-5 according to Equation (5):
Kiapp =
K′iapp
1+
(
[S]
KM
) (5)
Off rates (k-2 or koff) were measured using the jump-dilution method [41] (Figure S1c). AmpCEC
(1 µM) was incubated with the respective inhibitor (10 µM for TAN, CB2 and CB3, and 100 µM for
VAB) for 30 min at room temperature, then diluted 100,000 fold in the Assay Buffer (final enzyme
concentration: 10 pM) and immediately assayed with 25 µM FC-5. The data were fitted to Equation (2)
with V0 in this case representing the velocity of the no-enzyme control and VS representing the initial
velocity of uninhibited enzyme.
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The half-life of the enzyme-inhibitor complex t1/2 is given by Equation (6):
t1/2 =
ln(2)
ko f f
(6)
2.4. Antimicrobial Susceptibility Testing
Minimum inhibitory concentrations (MICs) were determined by broth microdilution in triplicate
and interpreted using published Clinical and Laboratory Standards Institute (CLSI) guidelines [22].
Ceftazidime (CAZ) was tested alone (0.25–256 µg mL−1) against DH5α Escherichia coli and DH5α
E. coli containing the pAD7-AmpCEC plasmid and in combination with CB2, CB3, TAN, and VAB (all
tested at a fixed concentration of 4 µg mL−1) using the DH5α E. coli strain containing the pAD7-AmpCEC
plasmid [38].
2.5. Crystallization Experiments, X-Ray Data Collection and Processing
Crystallization plates (low reservoir Intelli-Plate 93-3, Art Robbins Instruments, Sunnyvale, CA,
USA) were set up with a Phoenix RE Drop setter instrument (Art Robbins Instrument, Sunnyvale,
CA, USA). Crystals were grown via the vapor diffusion technique at room temperature. To obtain
AmpCEC-TAN and AmpCEC-CB3 complex crystals, crystals of apo-AmpCEC were grown in Condition
A, comprising 200 nL AmpCEC (20 mg/mL in 50 mM Tris pH 7.5), mixed with 200 nL Precipitant
Solution (10 mM zinc chloride, 100 mM MES pH 6.0 and 20% (w/v) PEG 6000). Crystals grew at room
temperature over 2–3 days, were transferred into a well solution supplemented with approximately
20 mM inhibitor and incubated for 15 and 10 min, respectively. These AmpCEC crystals are highly
sensitive to DMSO and prolonged soaking times (>15 min). Soaking was successful for TAN and
CB3, but, in the case of CB2, only low occupancy was observed for CB2 following soaking under the
same conditions. A single crystal of the AmpCEC-CB2 complex was obtained via co-crystallization
using Condition B, comprising 200 nL AmpCEC (18 mg/mL in 50 mM Tris pH 7.5) and CB2 (20 mM),
mixed with 200 nL Precipitant Solution (150 mM HEPES, 60% (v/v) 2-methyl-2,4-pentanediol (MPD)).
Crystals grew at room temperature over 1–2 weeks. Due to the less robust crystallization system
and the lower resolution of the data obtained (see Table S1), the co-crystallization approach was not
explored for TAN and CB3. Crystals were cryo-cooled and then stored in liquid nitrogen. Datasets
from single crystals were collected using the i03 and i24 MX beamlines at the Diamond Light Source
(Table S1). Structures were solved by molecular replacement in Phaser [42] using PDB ID 1IEM [43] as
the starting model. Alternating cycles of refinement using PHENIX [44] and model building using
Coot [45] were performed until Rwork and Rfree converged. Coordinates and structure factors have been
deposited in the Protein Data Bank. PDB IDs are 6T3D, 6YEO, 6YPD and 6YEN for the crystal structure
of AmpC from Escherichia coli in its apo-form and in complex with CB2, CB3, and TAN, respectively.
3. Results and Discussion
3.1. Kinetic Studies of AmpCEC Inhibition by Bicyclic Boronates
To investigate the importance of different side chains at the C-3 position (equivalent to C-6 of
penicillins or C-7 of cephalosporins) of the bicyclic boronate core for inhibition of AmpCEC, steady-state
kinetic assays (Table 1) were carried out using the fluorescent reporter substrate FC-5 [36]. All three
tested bicyclic boronates showed enhanced potency for AmpCEC inhibition compared to the monocyclic
boronate VAB (Kiapp ~ 1–4 µM for the bicyclic boronates, compared to 19 µM for VAB). Interestingly,
the thioether CB3 was slightly more potent against isolated AmpCEC than TAN and the structurally
similar compound CB2 (Kiapp 1µM for CB3, compared to 3µM and 4µM for CB2 and TAN, respectively).
The increased potency of CB3 likely results from accelerated binding (k2/K ~ 224× 103 M−1 s−1 compared
to ~ 81/86 × 103 M−1 s−1 for CB2/TAN and ~ 7 × 103 M−1 s−1 for VAB). However, dissociation of CB3 is
equally accelerated (21 × 10−3 s−1, compared to 3 × 10−3 s−1 for CB2/TAN and 0.7 × 10−3 s−1 for VAB),
resulting in a shorter half-life of the enzyme-inhibitor complex for CB3. This proposal is supported by
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pIC50 measurements showing equivalent potency of all three tested bicyclic boronates after a 10 min
pre-incubation period with AmpCEC (pIC50s of 7.5 for CB2, TAN, and CB3 compared to 6.3 for VAB).
Table 1. Kinetic analyses of AmpCEC inhibition by (bi)cyclic boronates in vitro. Kiapp values and pseudo
first-order rates (k2/K) were determined by assaying 100 nM AmpCEC with 5 µM FC-5 [36]. koff rates
were determined after jump-dilution (100,000 fold) of AmpCEC (1 µM) that had been pre-incubated
with cyclic boronates (10 µM for TAN, CB2 and CB3 and 100 µM for VAB) at room temperature for
30 min, then assayed using 25 µM FC-5. pIC50s were obtained from assays using 500 pM AmpCEC
and 5 µM FC-5 following a 10 min inhibitor pre-incubation at room temperature. Buffer: 50 mM Tris,
pH 7.5, 0.01% (v/v) Triton X-100. Data were analyzed as described in Materials and Methods.
Inhibitor Kiapp (µM) k2/K (M−1 s−1) × 103 koff (s−1) × 10−3 t1/2 (min) pIC50
VAB 19.1 ± 1.32 6.55 ± 0.46 0.69 ± 0.03 16.8 ± 0.7 6.32 ± 0.03
TAN 3.73 ± 0.50 85.6 ± 9.2 2.54 ± 0.51 4.55 ± 0.91 7.53 ± 0.02
CB2 3.26 ± 0.40 81.0 ± 6.4 2.77 ± 0.27 4.18 ± 0.41 7.49 ± 0.01
CB3 1.16 ± 0.14 224 ± 21 20.9 ± 12.8 0.55 ± 0.34 7.53 ± 0.02
3.2. Microbiology Experiments Confirm Potential of (Bi)cyclic Boronates to Inhibit AmpCEC in Cells
We then investigated the activity of VAB, TAN, CB2 and CB3 (fixed at 4 µg mL−1) in combination
with ceftazidime (CAZ) against E. coli DH5α producing AmpCEC (Table 2). Production of AmpCEC
substantially increased the extent of CAZ resistance (MIC 256 µg mL−1 compared to 1 µg mL−1 without
the AmpCEC expressing plasmid); all the tested inhibitors significantly restored CAZ activity against
the AmpCEC expressing strain. Despite the high potency of CB3 observed in the kinetic analyses
against isolated AmpCEC, it was less potent than CB2, TAN or VAB in restoring CAZ activity in the
engineered strain, i.e., CB3 reduced the MIC only to 4 µg mL−1, whereas the other inhibitors restored
the activity of CAZ to ≤ 1 µg mL−1.
Table 2. Microbiology analyses with vaborbactam (VAB), taniborbactam (TAN), cyclic boronate 2 (CB2)
and cyclic boronate 3 (CB3). All inhibitors were tested at a fixed concentration of 4 µg mL−1.
Minimum Inhibitory Concentration
Ceftazidime (µg mL−1)
Strain Plasmid CAZ CAZ (+ VAB) CAZ (+ TAN) CAZ (+ CB2) CAZ (+ CB3)
DH5α - 1 - - - -
DH5α pAD7AmpCEC
256 1 1 0.5 4
3.3. AmpCEC Crystal Structures with Bicyclic Boronates Give New Insights into Structural Basis of Inhibition
To investigate the structural basis of AmpCEC-inhibition by the three bicyclic boronates (CB2, TAN,
and CB3), we obtained crystal structures of their complexes with recombinant AmpCEC. The structures
of AmpCEC in complex with TAN (1.42 Å resolution, PDB ID: 6YEN) and CB3 (1.60 Å resolution, PDB
ID: 6YPD) were obtained by soaking of apo-AmpCEC crystals. A structure of the complex of AmpCEC
with CB2 (2.03 Å resolution, PDB ID: 6YEO) was obtained by co-crystallization (see Materials and
Methods). Apo-AmpCEC crystallized with a single chain in the asymmetric unit (space group P4332),
while the asymmetric unit of the AmpCEC-CB2 co-crystal complex contains four molecules of the
β-lactamase (space group P2221).
The overall fold of the AmpCEC-boronate complexes is very similar to that of the apo-AmpCEC
structure (PDB ID: 6T3D; main chain RMSDs with respect to the apo-structure: 0.39, 0.15, 0.07 Å for
CB2, TAN, and CB3, respectively, for chain A). In all three structures, analysis of the electron density
maps for the AmpCEC active site indicates that the bicyclic boronates CB2, TAN, and CB3 have reacted
with the nucleophilic S64 to form an anionic tetrahedral species in which the boron is sp3 hybridized
(Figure 2), as observed for other bicyclic boronate SBL complex structures [20,21,26,31–33]. The bicyclic
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core of all three inhibitors in complex with AmpCEC is bound in a similar manner to that observed
for cyclic boronate 1 (CB1, Figure 1d) in complex with the Pseudomonas aeruginosa AmpC (PDB ID:
6I30 [32]). In none of these cases did any of the active site bound bicyclic boronates form a tricyclic
structure, as was observed in crystallographic studies of the MBL NDM-1-TAN complex [24].
Figure 2. Structural basis for AmpCEC inhibition by bicyclic boronates. (a) reaction between
sp2-hybridized bicyclic boronates and SBLs give a serine-bonded anionic sp3-hybridized species;
(b) structures of serine-bonded sp3 forms of the bicyclic boronates; (c–e) active site views of complexes
of AmpCEC with CB2, CB3, and TAN. Hydrogen-bonding interactions are shown in colored dashes,
distances are in Å; (f) overlay of active site views, color coding as in (c–e). Note that the Q120 side chain
is rotated in AmpCEC-CB2 structure (highlighted in dark red); it is unclear whether this is induced by
binding of CB2, or due to the crystallization conditions (see text).
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The aryl carboxylic acid of the bicyclic boronates is positioned similarly to that of the monocyclic
inhibitor VAB as observed in complex with the Enterobacter cloacae AmpC (PDB ID: 4XUX [18]) and that
of CB1 observed in complex with P. aeruginosa AmpC [32]. The aryl carboxylic acid of all the bicyclic
boronates is involved in hydrogen-bonding or electrostatic interactions with active site residues K315,
T316, and N346. The boron-linked hydroxyl group engages in hydrogen-bonding interactions with the
backbone NH and oxygen of A318, as observed for the equivalent S345/338 residues in the P. aeruginosa
AmpC-CB1 and E. cloacae AmpC-VAB complex structures [18,32].
As observed in the P. aeruginosa AmpC-avibactam [46] and P. aeruginosa AmpC-relebactam [9,47]
complex structures, the amide nitrogen and carbonyl group of the TAN acylamino side chain are
positioned to make hydrogen-bonding interactions with active site residues, i.e., Q120, N152, and A318.
The cyclohexyl ring of TAN is directed out of the active-site R1 pocket (Figure 2e); only weak density
was observed for the likely disordered terminal alkyl-amine side chain, which was excluded from
the model.
AmpCEC was co-crystallized with CB2 giving crystals with four molecules in each asymmetric
unit, all of which manifested clear and continuous electron density for the covalently bound CB2 at the
active site (Figure S2). The overall folds and orientations of active site residues and CB2 (Figure S2d)
are very similar in all four chains (main chain RMSD of Chain B, C and D in relation to chain A: 0.31,
0.28, and 0.33 Å, respectively). Binding of the bicyclic boronate core of CB2, together with that of the
amido side chain group portion, is very similar to that observed for TAN (CB3 has a different type of
side chain).
Interestingly, in the CB2 structure, the side chain of Q120 is directed away from the active site in
all four molecules in the asymmetric unit (Figure 2c); Q120 interacts with a water molecule (Figure 2c,
‘w’, observed in all chains of the ASU), which in turn interacts with the carbonyl oxygen of the
acylamino CB2 side chain. In the apo structure of AmpCEC in condition A (PDB ID: 6T3D), the Q120
side chain is oriented towards the active site; however, the apparently weak density and elevated
B-factors for the Q120 side chain indicate partial disorder. The reorientation of the Q120 side chain
relative to the apo-enzyme observed in the AmpCEC-CB2 complex is not manifest in the structure
of the AmpCEC-TAN complex. Although the AmpCEC-CB2 complex was co-crystallized using a
different crystallization condition than for the two other structures reported here (see Materials and
Methods), because the Q120 side chain does not interact with residues of other AmpCEC molecules in
the crystalline lattice, reorientation due to formation of crystal contacts seems unlikely. In a crystal
structure of AmpCEC, obtained by soaking with CB2, partial density for the bound CB2 was observed
in the active site, though reorientation of the Q120 side chain was not observed (data not shown,
because of poor electron density for the CB2 C-3 side chain). It is thus unclear whether the different
orientation of Q120 compared to apo-AmpCEC is due to the different crystallization conditions or
due to a specific feature of CB2 binding. The positioning of the Q120 side chain could impact on the
potency of inhibition by bicyclic boronates containing an amido side chain, as in CB2 and TAN.
A structure of the AmpCEC-CB3 complex was obtained by soaking of apo crystals of theβ-lactamase.
CB3 does not contain the amido C-3 side chain, but instead features a benzyl-thioether side chain
(Figure 1d) [16]. CB3 was synthesized as a mixture of the (3S)- and (3R)-isomers with the (3R)-isomer in
excess (~24:76 (S:R) ratio) [16]. Although binding of low levels of the (3R)-isomer cannot be excluded,
only evidence for binding of the (3S)-CB3 was observed at the active site of AmpCEC. The thioether
side chain is partially disordered, as manifested by ~ 50% elevated B-factors compared to the CB3
average. The thioether is positioned to make hydrophobic pi-stacking interaction with Y221 (~ 4 Å
distance between Y221 and CB3 benzyl rings) and hydrophobic interactions with the side chains of
V211 and T319 in the R1 pocket (Figure 2d). These hydrophobic residues located on the AmpCEC
Ω-loop (residuess 185-225) are also present in the P. aeruginosa AmpC, rationalizing the high potency of
CB3 against both AmpCEC and P. aeruginosa AmpC and likely other class C SBLs, as reported here and
elsewhere [16]. Notably, mutations in the Ω-loop, e.g., deletion of Y221, have been observed to widen
the substrate specificity and also confer ceftazidime-avibactam resistance [12]. Such AmpC variants
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may be less susceptible to bicyclic boronates like CB3 and are thus a potential source of resistance to
such inhibitors. This is of particular concern given that mutations in the Ω-loop have been linked
to reduced susceptibility of cefepime against AmpC-expressing E. coli [48], which is the β-lactam
proposed for use in combination with TAN and which is not efficiently turned-over by the wildtype
AmpCEC.
Interestingly, apart from covalent modification of S64, analysis of the electron density map in
the structure obtained by soaking AmpCEC with TAN clearly reveals a second TAN molecule at the
interface between chain A and symmetry related molecules (Figure S3a). The second TAN molecule
adopts a U-shaped conformation in which its side chain folds over the bicyclic core (Figure 3); it is
positioned to form hydrogen-bonding interactions with multiple water molecules that interact with
the backbone carbonyls of P140, A141, and N102, and to make hydrophobic interactions with the side
chains of A143 and A98 in a symmetry related molecule (Figure 3a).
Figure 3. Comparison of bi- and tri-cyclic forms of sp3 hybridized taniborbactam in complex with
AmpCEC. (a) The tricyclic form of TAN as observed at the interface between symmetry related AmpCEC
molecules along a three-fold rotation axis (see Figure S3a for overview, PDB ID 6YEN). Residues
within 6 Å of TAN are shown as grey/purple sticks, hydrogen-bonding interactions as orange dashes,
and waters as red spheres; (b) structures of proposed bi- and tricyclic sp3 forms of TAN; (c) overlay of
the ‘interface’ tricyclic TAN (AmpCEC, orange) with active site bound tricyclic TAN (NDM-1, green);
(d) overlay of the ‘interface’ tricyclic TAN (AmpCEC, orange) with active site bound bicyclic TAN
bonded to AmpCEC S64 (yellow). Note, with the MBL NDM-1 (PDB ID: 6RMF), both the bicyclic and
the tricyclic forms were observed in one chain of the crystallographic dimer (chain A, shown here),
while, in the second chain, only the tricyclic form was observed [24].
Notably, with the surface bound TAN molecule, its C-3 amido side chain is rotated relative to
the conformation observed for bicylic TAN at the active site, positioning the carbonyl derived oxygen
atom in close proximity to the boron. Based on the short distance between the refined carbonyl
oxygen and the boron (1.5 Å), this molecule of TAN was thus modelled in a tricyclic form, as shown
in Figure 3b. The 5-membered ring of this TAN molecule was modelled in its unsaturated form
based on its planar conformation and the angle between the carbonyl-derived oxygen, carbon- and
amide-derived nitrogen atoms (122◦). The observation of tricyclic TAN on the surface of AmpCEC
indicates the viability of its formation in solution; reaction of acyl-amino side chains to form a ring onto
a proximate boronic acid has synthetic precedent [49]. An analogous tricycle has also been observed in
the complex formed between the B1 MBL NDM-1 and TAN [24]. Overlay of the tricyclic boronate core
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observed with AmpCEC and that observed in the active site of NDM-1 shows a strong resemblance
(Figure 3c); however, the side chains adopt different conformations in the two structures.
Importantly, overlays of the bicyclic portions of the tricyclic TAN core with the bicyclic TAN
reveals a steric clash for a potential tricycle, including its side chain, at the AmpCEC active site (Figure 4).
This analysis is consistent with the observed bicyclic structure at the AmpCEC active site and indicates
that it is unlikely that the boronates studied can bind to the AmpCEC active site in the tricyclic form (at
least without conformational change). Further comparisons suggest that the other SBLs, for which
crystallographic studies are reported in complex with the bicyclic form of TAN (i.e., KPC-2 [31] (PDB
ID 6TD1), CTX-M-15 [26] (PDB ID 6SP6), OXA-10 [24] (PDB ID 6RTN)), will also not accommodate
the tricyclic core, assuming a conserved general binding mode of the bicycle and no conformational
changes (Figure S5).
Figure 4. Tricyclic TAN likely cannot bind at the AmpCEC active site due to a steric clash of the
putative tricyclic core and side chain. (a) Structural comparison of tricyclic and bicyclic forms of TAN;
(b–g) overlay of tricyclic TAN core (orange, not crystallographically observed at AmpCEC active site)
with bicyclic TAN (yellow) crystallographically observed bound to active site S64 of AmpCEC (PDB
ID: 6YEN) reveals a likely steric clash of the rigid tricycle in the AmpCEC active site as well as active
sites of other β-lactamases (Figure S5). By contrast, both tricyclic (orange) and bicyclic (yellow) forms
of TAN have been crystallographically observed at the active site of the B1 MBL NDM-1 (PDB ID:
6RMF) [24]. Note, in both structures, that the terminal amine of the side chain was disordered and
therefore excluded from the model; (b) observed conformation of bicyclic TAN at the AmpCEC active
site; (c) alignment of tricyclic TAN core to bicyclic TAN observed at the AmpCEC active site; (d) putative
steric clash of tricyclic TAN in the AmpCEC active site based on the overlay in c). Note the apparently
flexible parts of the side chain are not shown, but would make a clear steric clash with the active site;
(e) observed conformation of bicyclic TAN at the NDM-1 active site; (f) overlay of tricyclic TAN and
bicyclic TAN, both as observed at the NDM-1 active site; (g) observed conformation of tricyclic TAN at
the NDM-1 active site.
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Although there are substantial differences in the active site chemistry of the SBLs and MBLs,
crystallographic analysis on the class B1 MBL VIM-2 [26] (PDB ID: 6SP7) shows that the bicyclic
conformation of TAN as observed in SBLs is maintained in binding to this clinically relevant MBL
(Figure S5). In the case of NDM-1, active site binding of both bicyclic and tricyclic TAN was observed as
shown in Figure 4e–g (~75% of the active sites were occupied by the tricyclic and ~25% by the bicyclic
form) [24]. By contrast, overlay of the tricyclic form of TAN with the bicyclic form of TAN as observed
in the active site of VIM-2 reveals a steric clash (Figure S5). This implies that the tricyclic form of TAN
is likely relevant to the inhibition of some (NDM-1), but not all MBLs, assuming a conserved binding
mode for the tri-/bi-cycle core and a lack of substantial conformational changes. It should be noted
that recent work has shown other tricyclic boronates, i.e., those containing a cyclopropyl group fused
to the C2/C3 carbons of the bicyclic boronate potently inhibit both SBLs and MBLs [50], though the
cyclopropyl ring methylene projects in a different orientation to the ‘third’ ring of the tricyclic ring
system that can be formed with TAN (Figure S6).
4. Conclusions
Following the clinical application of boronic acids as proteasome inhibitors for treatment of
myeloma, boronic acids/boronates have become more common in medicinal chemistry [17]. In the
antibacterial field, the monocyclic boronate vaborbactam has been approved for clinical use as an
inhibitor of class A and some class C SBLs [19]. More recent work has demonstrated that the scope of
boronates as β-lactamase inhibitors can be extended to multiple SBLs and MBLs by integration into a
bicyclic scaffold [20,21], as present in TAN [26] (Figure 1d), which is currently in late stage clinical trials.
Our kinetic and structural studies with TAN and other bicyclic boronate derivatives (CB2, CB3) with
different C-3 side chains reveal their potential for inhibition of the class C AmpC serine-β-lactamase
from Escherichia coli.
Our results further support the potential of bicyclic boronates as unusually broad-spectrum
inhibitors of all SBL types and, at least B1 type, MBLs. It is possible that the potential of cyclic boronates
as clinically useful inhibitors of two or more mechanistically distinct groups of enzymes will extend to
other families, such as proteases. Improvements in methods for their preparation should enable more
systematic SAR. In this regard, it may be that the incorporation of the boron into a ring system that
limits conformations and modes of reactivity may both enhance potency and reduce unwanted modes
of reaction (e.g., oligomerization) compared to acyclic boronic acids.
Combined with previous reports, our three crystal structures of bicyclic boronates with
AmpCEC reveal remarkable similarity between the binding modes of the 6,6-core ring system of
the bicyclic boronates to SBLs from class A (e.g., CTX-M-15 [21,26], L2 [33], and KPC-2 [31]),
class D (e.g., OXA-10 [20,24]) and the class C AmpC from Pseudomonas aeruginosa [32] as well as
the penicillin-binding protein-5 (PBP-5) from Escherichia coli [20]. The results thus support the proposal
that mimicking high-energy intermediates common to different types of enzymes can enable their
inhibition by the same inhibitor. Note that the reported bicyclic boronates tend to be weaker PBP
inhibitors (and hence antibiotics) than SBL/B1 MBL inhibitors [20,21]; this may reflect the fact that,
although they react withβ-lactams, PBPs are not optimized to catalyze their hydrolysis. Alternatively, it
may be that optimized functionalization of the core bicyclic boronate will enable potent PBP inhibition.
The combined results show that, in the case of SBL/MBL inhibition by bicyclic boronates, there is scope
for (C-3) side chain optimization, which may further broaden the scope of β-lactamase inhibition,
including to multiple B2/B3 type MBLs. Optimization in potency will need to be carried out in
parallel with that at a microbiological level, as has been done for TAN with respect to improved
cell penetration [26]. Interestingly, although VAB was substantially less potent than TAN against
isolated AmpCEC, it performed equally well against our AmpC bearing engineered E. coli strain as
TAN (Table 2), possibly reflecting either improved penetration or reduced efflux.
Together with previous reports showing enhanced activity of CB3 against class D SBLs, as well as
certain B2 and B3 MBLs compared to TAN and CB2 [16], our results suggest the thioether CB3 could be
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a promising start for further optimization towards a broad-spectrum, dual SBL and MBL inhibitor.
Selective binding of the minor (3S)-isomer indicates that stereoselective synthesis might further benefit
AmpCEC inhibition. Further optimization will need to address the relatively low potency of CB3
in cells, which could reflect potential poor cell penetration of CB3 due to its lipophilicity. CB3 has
a predicted logP of 4.42; studies have shown that compounds with relatively low logPs (e.g., CB2,
TAN and VAB with predicted logPs of 2.09, 1.50, and 1.86, respectively) manifest improved penetration
of Gram-negative bacteria [51], leaving further scope for optimization of the thioether side chain, e.g.,
by addition of an amino group as in TAN [26].
The observation of an apparently weakly bound tricyclic form of TAN on the surface of AmpCEC
is of interest from a boronate chemistry perspective as it potentially further exemplifies the ability
of boron-based inhibitors to interchange between different forms in aqueous solution. It should be
noted that, in both the cases where a tricyclic boronate form has been observed crystallographically,
i.e., with AmpCEC and the MBL NDM-1, the crystallization conditions were acidic (pH 6.0 and 5.8 [24],
respectively). Thus, the tricycle could be formed in aqueous solution during crystallization; such
formation in aqueous solution is precedented in small molecule chemistry [49]. Comparison of SBL
and MBL structures with tri- and bi-cyclic boronates suggests most SBL active sites will not readily
accommodate tricylic structures of the type reported here and previously [24]. Although tricyclic
TAN likely does not significantly contribute to inhibition of AmpCEC and related SBLs, at least one
β-lactamase (NDM-1) can bind a tricyclic form at its active site (at least in crystals) [24], thus the ability
of boronate type inhibitors to interchange between different forms has the potential to extend the range
of β-lactamases usefully inhibited by them.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/6/899/s1,
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to some β-lactamases including members from all Ambler classes. Figure S6: Structures of the tricyclic form of
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